Information  X 
Enter a valid email address

Hikma Pharmaceutical (HIK)

  Print          Annual reports

Monday 17 May, 2021

Hikma Pharmaceutical

Director/PDMR Shareholding

RNS Number : 8929Y
Hikma Pharmaceuticals Plc
17 May 2021
 

 

Hikma Pharmaceuticals PLC - EIP B and EIP C Vesting

LONDON, 17 May 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards which were granted on 17 May 2019 under the 2014 Executive Incentive Plan ("EIP") Element B and granted on 16 May 2018 under the 2014 EIP Element C.  The Element B awards vested two years after grant and the Element C awards vested three years after grant.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 12,042

d)

Aggregated information

Volume
 

Price

 

Total

 

12,042

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 22,601

d)

Aggregated information

Volume
 

Price

 

Total

 

 

22,601

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 15,855

d)

Aggregated information

Volume
 

Price

 

Total

 

 

15,855

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 25,729

d)

Aggregated information

Volume
 

Price

 

Total

 

 

25,729

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 23,062

d)

Aggregated information

Volume
 

Price

 

Total

 

 

23,062

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Susan Ringdal

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Susan Ringdal

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
16 May 2021 under the EIP Element C.  Shares were sold to cover tax and the remainder were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 7,522

 

Price(s): £23.835

Volume(s): 6,735

d)

Aggregated information

Volume
 

Price

 

Total

 

 

14,257

£23.835

£160,528.73p

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Hussein Arkhagha

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Hussein Arkhagha

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Shares acquired from the vesting of conditional awards on
17 May 2021 under the EIP Element B.  All Shares were retained.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 11,246

d)

Aggregated information

Volume
 

Price

 

Total

 

 

11,246

£0.00

£0.00

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760

17 May 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBSGDUUUBDGBR

a d v e r t i s e m e n t